This structured approach allows for a more nuanced understanding of the therapeutic potential and limitations of pertuzumab-based regimens, emphasizing their role as a cornerstone in the treatment of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.